home.social

#eligiblepatients — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #eligiblepatients, aggregated by home.social.

  1. PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

    Moitreyee Chatterjee-Kishore, PhD, MBA, Head of Oncology Development, Astellas“Building on the recent U.S. approval for cisplatin-ineligible patients living…
    #NewsBeep #News #Medication #adjuvanttreatment #adversereactions #AU #Australia #BladderCancer #eligiblepatients #Health #MIBC #neoadjuvant #PADCEV #pembrolizumab
    newsbeep.com/au/354946/

  2. PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

    Moitreyee Chatterjee-Kishore, PhD, MBA, Head of Oncology Development, Astellas“Building on the recent U.S. approval for cisplatin-ineligible patients livin…
    #NewsBeep #News #Medication #adjuvanttreatment #adversereactions #bladdercancer #eligiblepatients #Health #MIBC #neoadjuvant #PADCEV #pembrolizumab #UK #UnitedKingdom
    newsbeep.com/uk/321667/

  3. Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

    Geron Corporation Oral presentation from pooled analyses of the IMerge population suggests that treatment-emerg…
    #NewsBeep #News #Medication #CA #Canada #eligiblepatients #GeronCorporation #Health #IMerge #imetelstat #LR-MDS #MDSpatients #posterpresentations #RYTELO #treatmentoptions
    newsbeep.com/ca/334044/

  4. europesays.com/ie/222138/ Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS #Éire #EligiblePatients #GeronCorporation #Health #IE #IMerge #imetelstat #Ireland #LRMDS #MDSPatients #Medication #PosterPresentations #RYTELO #TreatmentOptions

  5. Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

    Geron Corporation Oral presentation from pooled analyses of the IMerge popula…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #eligiblepatients #GeronCorporation #Health #IMerge #imetelstat #LR-MDS #MDSpatients #posterpresentations #RYTELO #treatmentoptions
    newsbeep.com/us/337199/

  6. Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

    Geron Corporation Oral presentation from pooled analyses of the IMerge popula…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #eligiblepatients #GeronCorporation #Health #IMerge #imetelstat #LR-MDS #MDSpatients #posterpresentations #RYTELO #treatmentoptions
    newsbeep.com/us/337199/